Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Elias Jabbour

Academic history

Elias Jabbour, MD, is a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, Houston, TX. Prof. Jabbour received his medical degree from Saint Joseph University in Beirut (1998), Lebanon. Following this, he completed a clinical residency at the same university, where he also got a master’s degree in Biological Sciences (1999).

In 1999, Prof. Jabbour received a certificate from the Educational Committee for Foreign Medical Graduates in Philadelphia, PA. In 2001, he undertook a clinical fellowship to work in Hematology-Oncology at the Gustave Roussy Institute in Villejiuf, France. In 2003, Prof. Jabbour joined the University of Texas MD Anderson Cancer Center as a Clinical Fellow working on leukemia (2003-2005) and Blood and Marrow Transplantation (2005- 2007).

Prof. Jabbour has two university diplomas, one in Clinical Carcinology (University of Paris XI School of Medicine, Paris, France – 2002) and another in Hematology, Clinic and Biologic Options (University of Paris V School of Medicine, Paris, France -2003). He also has a specialist diploma in Hematological-Oncology from Saint Joseph University School of Medicine in Beirut, Lebanon (2005).

Prof. Jabbour is a member of the Society of Hematologic Oncology in Houston, TX, and is certified by the Lebanese Boards of Hematology and Oncology. Prof. Jabbour is Chief of the Acute Lymphocytic Leukemia section in the Department of Leukemia at the MD Anderson Cancer Center.

Speaking on leukemia and lymphoma

Prof. Jabbour’s research interests focus on developmental therapeutics in leukemia. In his clinical practice, Prof. Jabbour is interested in the mechanism of resistance to tyrosine kinase inhibitors, the development of monoclonal antibodies for adult ALL and tests of triple therapy in AML. Currently, he is the Principal Investigator of numerous clinical trials.